drugset / Trial / NCT00838526

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00838526

Phase 3 Completed 240 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

Timeline

Start
2008-08-31
Primary completion
2009-07-31
Completion
2009-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 50 mg Oral
Comparator Ranitidine Unknown 150 mg Oral